exhibit 10. 4 confidential materials omitted and filed separately with the securities and exchange commission. * * * triple asterisks denote omissions. scope of work # 2 this scope of work is incorporated into the master services agreement dated july 20, 2017 by and between arqule and arup ( for the purposes of this scope of work, the “ agreement ” ). this scope of work describes services and deliverables to be performed and provided by arup pursuant to the agreement. in the event of any conflict between the agreement and any provision of this scope of work, the agreement will control unless the parties ’ intent to alter the terms of the agreement is expressly set forth in such provision, and such alteration shall apply only to this scope of work and shall not be construed as an amendment to the terms of the agreement or to any other scope of work. all capitalized terms used and not expressly defined in this scope of work will have the meanings given to them in the agreement. overview the goals of this scope of work ( sow ) are the performance of clinical specimen testing to support arqule ’ s registrational phase 3 trial with arq 087 in subjects with fgfr2 gene fusion positive inoperable or advanced intrahepatic cholangiocarcinoma ( the “ phase 3 trial ” ) and the development of a clinical module to be included in the hde application for the companion diagnostic for arq 087, the fgfr2 fish assay ( as more fully described in sow # 1 ). the end point for the existing trial is overall response rate. the parties acknowledge that arqule may decide to pursue a trial endpoint of progression free survival. in such case, arqule agrees to keep arup apprised of its decision making, and the details of the new trial and protocol for the study will be shared with arup if and when made. for purposes hereof, either trial shall be known as the phase 3 trial. this sow functions in support of sow # 1 by contributing to the clinical understanding of the assay. sow # 1 functions to support this sow, since it covers the development, and analytical validation of the fgfr2 fish assay that is used for the clinical testing. approach 1. arup will utilize the fgfr2 fish assay developed and validated in sow # 1 to test ffpe clinical specimens from